ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

Identification of Atovaquone, Ouabain and Mebendazole as FDA Approved Drugs Tar-geting SARS-CoV-2 (Version 4)

preprint
revised on 13.05.2020, 22:37 and posted on 14.05.2020, 13:02 by Ayman Farag, Ping Wang, Ian N. Boys, Jennifer L. Eitson, Maikke B. Ohlson, Wenchun Fan, Matthew B. McDougal, Mahmoud Ahmed, John W. Schoggins, Hesham Sadek

The newly emerged coronavirus, SARS-CoV-2, and the resulting COVID-19 disease, has spread swiftly across the globe since its initial detection in December 2019. Given the heavy toll of this pandemic, therapeutic options for treatment are urgently needed. Here, we adopted a repositioning approach using in-silico molecular modeling to screen FDA-approved drugs with established safety profiles for potential inhibitory effects against SARS-CoV-2. We used structure-based drug design to screen more than 2000 FDA approved drugs against SARS-CoV-2 main protease enzyme (Mpro) substrate-binding pocket, focusing on two potential sites (central and terminal sites) to identify hits based on their binding energies, binding modes, interacting amino acids, and therapeutic indications. We additionally screened the top hits from both sites for potential covalent binding via nucleophilic thiol attack of Cys 145. High-scoring candidates were then screened for antiviral activity against infectious SARS-CoV-2 in a cell-based viral replication assay, and counterscreened for toxicity. Atovaquone, Mebendazole, and Ouabain exhibited antiviral efficacy with IC50s well within their respective therapeutic plasma concentrations (low nanomolar to low micromolar range), and limited toxic effects. Notably, all three were predicted in docking studies to covalently bind SARS-CoV-2 Mpro, underscoring the utility of this in-silico approach for identifying putative antivirals for repurposing. These results do not confirm efficacy in animal models or in humans, but rather serve as a starting point for testing the antiviral potential of select FDA-approved drugs, either individually or in combination.

Funding

Center for Regenerative Science and Medicine, UT Southwestern Medical Center

History

Email Address of Submitting Author

hesham.sadek@utsouthwestern.edu

Institution

UT Southwestern Medical Center

Country

USA

ORCID For Submitting Author

https://orcid.org/0000-0002-4745-366X

Declaration of Conflict of Interest

None

Version Notes

Version 2 expanded docking analysis to include the terminal domain of the Mpro substrate binding pocket which revealed additional potential hits. Viral assays confirmed the antiviral activity of 3 of the top 7 hits predicted to bind covalently to the substrate binding pocket

Exports

Logo branding

Exports